Gilead's Compassionate Use Data Promising, But Imminent COVID-19 Treatment Shift Unlikely
Executive Summary
Interpretation of remdesivir's compassionate use data is complicated by typical disease course of COVID-19 patients. The uncontrolled data raises hopes for positive trials but is unlikely to change current treatment protocols.
You may also be interested in...
Remdesivir Shows Promising Results In Leaked Report But Doubts Remain
Gilead’s front-running antiviral to fight the coronavirus has shown rapid improvement in severe patients’ symptoms in one US study but some are not convinced.
Coronavirus Update: Remedesivir China Trials Halted, Witty To Spearhead WHO's Vaccines Efforts
Plus: Korean firms working on repurposed drug which showed far higher efficacy than remdesivir and chloroquine in pre-clinical tests
Indian Industry Gets HCQ, Paracetamol Exports Rolling
Indian manufacturers hope increased production of hydroxychloroquine and paracetamol, along with emergence of reliable COVID-19 therapies, will lead to export restrictions on these two medicines being removed soon. Meanwhile, they are fulfilling orders routed through the government.